South Korean regenerative medicine company Medipost announced the clinical study results of usage ’Pneumostem’ for chronic pulmonary disease treatment in premature babies. to be published in international academic journal ‘The Journal of Pediatrics’ (Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial)
Medipost together with Samsung Seoul Hospital, Medical School of Seongkyunkwan University successfully finished Phase 1 clinical study of premature baby chronic pulmonary disease treatment drug ‘Pneumostem’. Phase 2 clinical study is progress now.
Premature baby chronic pulmonary disease is the most important causal disease of death and complications in premature babies with no special treatment method so far. In this clinical study, the research team proved the safety and efficacy of ’Pneumostem’ in intratrachracheal transplantation targeting 9 premature babies of 24-26 weeks into pregnancy when there is very high risk of premature baby chronic pulmonary disease.
In particular, while the occurrence of severe premature baby chronic pulmonary disease remained at 72% in existing high risk group premature babies, it decreased to less than half being 33% in the ‘Pneumostem’ treatment group, confirming treatment efficacy and possibility. Levels of interleukin-6, interleukin-8, matrix metalloproteinase-9, tumor necrosis factor α, and transforming growth factor β1 in tracheal aspirates at day 7 were significantly reduced compared with those at baseline or at day 3 posttransplantation. BPD severity was lower in the transplant recipients, and rates of other adverse outcomes did not differ between the comparison group and transplant recipients.
‘Pneumostem’ are allogeneic cord blood derived mesenchymal stem cells.